scholarly journals Hyperbaric Oxygen Therapy for Suburethral Vaginal Mucosal Necrosis after Interstitial Irradiation for Recurrent Cervical Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Yoshihisa Arakaki ◽  
Yuko Shimoji ◽  
Tadaharu Nakasone ◽  
Yusuke Taira ◽  
Tomoko Nakamoto ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
High Dose Rate ◽  
Japanese Woman ◽  
Absolute Pressure ◽  
High Dose ◽  
Recurrent Cervical Cancer ◽  
Soft Tissue Necrosis

Patients with gynecological malignancies can develop radiation injuries, such as cystitis, proctitis, and soft tissue necrosis which have approved indications for hyperbaric oxygen therapy (HBOT). A 76-year-old Japanese woman with vaginal recurrence of cervical cancer was treated with the high-dose rate interstitial brachytherapy. Twenty-one months after the irradiation, she developed radiation necrosis on the external urethral opening. Two cycles of HBOT were performed. HBOT consisted of delivering 100% oxygen for 60 minutes at 2.4 atmospheres absolute. Pressure exposure was performed once daily, 5 days a week for 6 weeks. Eventually, the necrotic mucosa was completely replaced by the normal mucosa. No adverse effects were observed. We successfully treated a case of late adverse events of radiation therapy with HBOT. It was noninvasive and appears to be a useful treatment option which should be considered standard treatment practice.

High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease

2003 ◽  
Vol 91 (1) ◽  
pp. 258-260 ◽  
Author(s):  
Ted M Roth ◽  
Angeles Alvarez Secord ◽  
Laura J Havrilesky ◽  
Ellen Jones ◽  
Daniel L Clarke-Pearson
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
Intraoperative Radiotherapy ◽  
High Dose Rate ◽  
High Dose ◽  
Nodal Disease ◽  
Recurrent Cervical Cancer

Reirradiation Using High-Dose-Rate Interstitial Brachytherapy for Locally Recurrent Cervical Cancer: A Single Institutional Experience

2014 ◽  
Vol 24 (1) ◽  
pp. 141-148 ◽  
Author(s):  
Seiji Mabuchi ◽  
Ryoko Takahashi ◽  
Fumiaki Isohashi ◽  
Takeshi Yokoi ◽  
Mika Okazawa ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Dose Rate ◽  
Palliative Therapy ◽  
High Dose Rate ◽  
Interstitial Brachytherapy ◽  
Clinical Variable ◽  
High Dose ◽  
Recurrent Cervical Cancer

ObjectivesThis study aimed to evaluate the effectiveness and feasibility of reirradiation using high-dose-rate interstitial brachytherapy (HDR-ISBT) in patients with recurrent cervical cancer.MethodsThe records of 52 consecutive women with central pelvic recurrence who were salvaged with HDR-ISBT–based reirradiation were retrospectively reviewed. Data regarding the primary disease, follow-up findings, recurrence, the treatment outcome, and toxicities were collected. Multivariate analysis was performed using the Cox proportional hazards regression model to identify predictors of the response to HDR-ISBT. Survival rate was calculated using the Kaplan-Meier method and compared using the log-rank test.ResultsA total of 52 patients who had been treated with HDR-ISBT–based reirradiation were included in our database. The local control rate was 76.9% (40/52), and the median postrecurrence survival period was 32 months. Grade 3 or 4 late toxicities were observed in 13 patients (25%). Multivariate analysis revealed that tumor size and the treatment-free interval were significant poor prognostic factors of postrecurrence survival. In a comparison between the patients who were salvaged with HDR-ISBT–based reirradiation (ISBT group) and those who were treated with palliative therapy alone (palliative group), we found that among the patients who displayed 0 or 1 poor prognostic factors, the patients in the ISBT group survived significantly longer than those in the palliative group. In contrast, similar survival rates were seen in both groups among the patients with 2 or more poor prognostic factors.ConclusionsReirradiation using HDR-ISBT is effective and feasible in patients with recurrent cervical cancer. Our 2-clinical variable prognostic model might enable physicians to identify patients who would not derive clinical benefit from HDR-ISBT and offer them the opportunity to receive other types of treatment.

scholarly journals Reirradiation with High-Dose-Rate Brachytherapy in Recurrent Cervical Cancer - An Update

Brachytherapy ◽  
2016 ◽  
Vol 15 ◽  
pp. S91 ◽  
Author(s):  
Shirley C. Lewis ◽  
Umesh Mahantshetty ◽  
Reena Engineer ◽  
Supriya Chopra ◽  
Nikhil Kalyani ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Recurrent Cervical Cancer

Hyperbaric oxygen therapy for paediatric patients: an unintended consequence of the COVID-19 pandemic

2021 ◽  
Vol 30 (Sup9) ◽  
pp. S24-S28
Author(s):  
Areeg A Abu El Hawa ◽  
Jenna C Bekeny ◽  
Nituna W Phillips ◽  
Kelly Johnson-Arbor
Keyword(s):  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Skin Flap ◽  
Healthcare Delivery ◽  
Geographic Region ◽  
Anxiety Reduction ◽  
Adjunctive Treatment ◽  
Paediatric Patients ◽  
Soft Tissue Necrosis

Objective: Hyperbaric oxygen therapy (HBOT) is a useful adjunctive treatment for selected complicated wounds, including severe diabetic lower extremity ulcerations and compromised skin grafts or flaps. The Sars-CoV-2 (COVID-19) pandemic has disrupted healthcare delivery, with its effects extending to delivery of HBOT. During the pandemic, paediatric patients in our geographic region who were referred for HBOT faced challenges as centres temporarily closed or were unprepared to treat younger patients. Our monoplace HBOT centre modified existing practices to allow for treatment of these patients. This study aims to outline the steps necessary to adapting a pre-existing HBOT centre for the safe treatment of paediatric patients. Method: A retrospective review was performed to identify patients 18 years of age or younger referred for HBOT during 2020. Patient characteristics, referral indications and HBOT complications were collected. Changes implemented to the HBOT centre to accommodate the treatment of paediatric patients were documented. Results: A total of seven paediatric patients were evaluated for HBOT and six were treated. The mean patient age was four years (range: 1–11 years). Referral diagnoses included sudden sensorineural hearing loss, skin flap or graft compromise, and radiation-induced soft tissue necrosis. All patients tolerated HBOT treatment in monoplace chambers without significant complications noted. Enhancements made to our clinical practice to facilitate the safe and effective treatment of paediatric patients included ensuring the availability of acceptable garments for paediatric patients, maintaining uninterrupted patient grounding (in relation to fire safety), and enhancing social support for anxiety reduction. Conclusion: The results of our review show that paediatric patients can be safely treated within the monoplace hyperbaric environment.

The efficacy of hyperbaric oxygen therapy in the treatment of medically refractory soft tissue necrosis after penile brachytherapy

Brachytherapy ◽  
2011 ◽  
Vol 10 (6) ◽  
pp. 491-497 ◽  
Author(s):  
Alfonso Gomez-Iturriaga ◽  
Juanita Crook ◽  
Wayne Evans ◽  
Elantholi P. Saibishkumar ◽  
John Jezioranski
Keyword(s):  
Soft Tissue ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Tissue Necrosis ◽  
Soft Tissue Necrosis

High dose rate intracavitary brachytherapy for recurrent cervical cancer of the vaginal stump following hysterectomy

1991 ◽  
Vol 20 (5) ◽  
pp. 927-932 ◽  
Author(s):  
Hisao Ito ◽  
Hideo Kumagaya ◽  
Naoyuki Shigematsu ◽  
Iku Nishiguchi ◽  
Toshitake Nakayama ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
Intracavitary Brachytherapy ◽  
High Dose ◽  
Recurrent Cervical Cancer
Sign in / Sign up

Export Citation Format

Share Document